CANbridge Pharmaceuticals
Beijing, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Biopharma company bridging global rare disease and oncology therapies to the China market and beyond.
Rare DiseaseOncologyGene Therapy
Technology Platform
Hybrid model combining in-licensing of late-stage therapies with an emerging internal gene therapy platform based on novel AAV vectors.
Opportunities
The significant unmet medical need in China's rare disease space and the company's established regulatory and commercial infrastructure provide a strong growth platform.
Risk Factors
Dependence on successful clinical outcomes of key late-stage pipeline candidates and the high cost of gene therapy development and commercialization are major risks.
Competitive Landscape
Faces competition from both global pharma giants launching their own products in China and domestic biotechs developing similar rare disease therapies.